Home›Trial›NCT04899310
🔬NCT04899310Phase 1Phase 2ACTIVE NOT RECRUITING

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Study Summary

This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency. The main goal of the study is to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intravenously (IV)-infused mRNA-3705.

Conditions
Methylmalonic Acidemia
Interventions / Drugs
mRNA-3705Placebo
View on ClinicalTrials.gov ↗
Sponsor
MRNA
Moderna Inc
mRNA Therapeutics
C53/100
Study Details
Enrollment74 participants
Primary Completion—
Lead SponsorModernaTX, Inc.
Data Retrieved2026-04-11 02:55:38.209232+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.